Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 65
- 试验地点
- 12
- 主要终点
- Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0
研究概览
简要总结
The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine and oxaliplatin) treatment failure in patients with metastatic colorectal cancer.
详细描述
Phase II portion is an open-label, single arm study. Based on the results of the Phase I portion, weekly KRN330 (0.5 mg/kg) and biweekly irinotecan (180 mg/m2) will be used in the Phase II portion. To be eligible for the Phase II portion, a patient will have recurred or progressed within 6 months of the last cycle of FOLFOX/CapOx +/- bevacizumab (first-line or adjuvant regimen for metastatic colorectal cancer). Patients will continue the treatment until disease progression.
Per protocol, the decision was made to terminate the study based on interim analysis results. The Response Rate in Phase II did not meet the protocol-specified RR of 15% when 0.5 mg/kg KRN330 was administered weekly in combination with irinotecan(180 mg/m2)biweekly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have histologically confirmed colorectal cancer that is metastatic with measurable disease.
- •For the Phase II portion: Have recurred or progressed within 6 months of the last cycle of FOLFOX +/- bevacizumab first-line or adjuvant regimen for metastatic colorectal cancer. Note: Those who had initiated FOLFOX/CapOx but stopped oxaliplatin because of intolerable toxicity are also eligible.
- •At least 4 weeks have elapsed since the last chemotherapy, radiotherapy, immunotherapy, or biologic therapy prior to enrollment (except at least 6 weeks in the case of nitrosourea and mitomycin).
- •Have not received any other investigational agents within 4 weeks of study entry and have fully recovered from any adverse event due to prior therapy.
- •At least 4 weeks have elapsed since any major surgery.
- •Have ECOG performance status of 0, 1, or
- •Have adequate bone marrow and organ function
排除标准
- •Have an active, uncontrolled infection.
- •Have known HIV positive status.
- •Have known or suspected cerebral metastasis.
- •Have had a myocardial infarction (MI) or cerebrovascular accident (CVA) within the last 6 months; or meet the criteria for AHA class III or IV congestive heart failure (CHF).
- •Have a medical condition requiring chronic use of high-dose corticosteroids or other chronic immunosuppressive therapy (e.g. methotrexate, azathioprine).
- •Have a history of greater than or equal to Grade 2 allergic reaction or hypersensitivity following exposure to humanized or human monoclonal antibodies (but not chimeric antibodies).
- •Pregnant or breastfeeding women and male or female patients who do not agree to use effective contraceptive method(s) during the study.
研究组 & 干预措施
KRN330 + Irinotecan
open label, single arm
干预措施: KRN330 (Biological)
KRN330 + Irinotecan
open label, single arm
干预措施: Irinotecan (Drug)
结局指标
主要结局
Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0
时间窗: Until disease progression, death, or withdrawal post initial KRN330 treatment, assessed up to 100 months
次要结局
未报告次要终点